You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Developing a novel adjuvant system for therapeutic vaccines against lung cancer
SBC: FasCure Therapeutics LLC Topic: 102DESCRIPTION provided by applicant Therapeutics is focused on the development of adjuvant systems with desired immune activities for targeted indications The Companyandapos s immune stimulatory adjuvant platform builds on combinatorial use of immune agonists with distinct immune targets and mechanisms of action for the generation of therapeutic immune responses Critical to this platform techno ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
PlusOne: Prototyping and Validation of a Wireless In-Home Breathing Monitor for Prevention of Overdose Deaths
SBC: Xandem Technology LLC Topic: NIDADESCRIPTION provided by applicant This proposal investigates the use of a novel passive personal monitoring system to stem the tide in the epidemic of deaths due to unintentional opioid drug overdoses In the U S in opioid drug overdoses including prescription pain relievers and heroin caused deaths a number that has increased dramatically over the past two decades A person w ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Aminopiperidines as novel anti influenza agents
SBC: Chicago Biosolutions, Inc. Topic: NIAIDInfluenza A viruses belong to the orthomyxoviridae family with a negative sense segmented RNA genome which can cause seasonal or pandemic flu with high morbidity and significant mortality Vaccination is the most prevalent prophylactic means for controlling influenza infections However an effective vaccine usually takes at least months to develop for the circulating strains Furthermore vac ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Monochromatic 222 nm UV light: Development of a safe, cost-effective technology for the efficient reduction of bacterial and viral infection and transmission
SBC: EDEN PARK ILLUMINATION, INC. Topic: NIAIDDESCRIPTION provided by applicant Drug resistant bacteria such as MRSA and airborne transmitted microbes such as influenza and TB together present major health issues both in the developed and the developing world with major health care and economic consequences Recent research from Columbia University Medical Center demonstrated that single wavelength far UVC photons can kill bacteria a ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
A chimeric protein for the selective expansion of regulatory T cells
SBC: SAHANE BIOTECH INC Topic: NIAIDDESCRIPTION provided by applicant Type diabetes T D is a chronic disease caused by the autoimmune destruction of the insulin producing beta cells in the pancreas Current treatment options for T D are severely limited All patients diagnosed with T DM are placed on life long insulin therapy and the current standard of care for adult patients with T DM is intensive diabetes therapy to avoid ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Clinical Text Automatic De-Identification to Support Large Scale Data Reuse and Sharing
SBC: Clinacuity, Inc Topic: 400DESCRIPTION provided by applicant The adoption of Electronic Health Record EHR systems is growing at a fast pace in the U S and this growth results in very large quantities of patient clinical data becoming available in electronic format with tremendous potentials but also equally growing concern for patient confidentiality breaches Secondary use of clinical data is essential to fulfill ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Developing a method to increase HIV testing among YMSM
SBC: RESILIENT GAMES STUDIO, LLC Topic: NICHDDESCRIPTION provided by applicant Adolescents are particularly vulnerable to HIV and account for one quarter of all new infections each year Most new infections among adolescents occur among young men who have sex with men YMSM Transmission of HIV can be virtually eliminated by treatment but testing rates are low and a significant proportion of YMSM are unaware of their HIV status P ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
An Ultra filtrate perfusion bio artificial pancreas for high-density islet replacement without immunosuppression
SBC: Norfolk Medical Products, INC. Topic: NIDDKDESCRIPTION provided by applicant The Cell SafeTM is a fundamentally new approach in replacement of dysfunctional insulin producing cells in patients with diabetes by transplantation of new islets in a three dimensional scaffold embedded in a highly compatible bioengineered perfusion system that continuously supplies tissue fluid blood ultrafiltrate so that the cells ae protected from immun ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Aminomethyl benzamides as novel anti Ebola agents
SBC: Chicago Biosolutions, Inc. Topic: NIAIDEbola EBOV and Marburg MARV viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as the biosafety level agents Currently there is no effective vaccine or therapeutic treatment against filoviral infection and pathogenes ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Target Identification for Novel Small Molecule Therapeutic for Alzheimer's disease
SBC: CoPlex Therapeutics, LLC Topic: NIAABSTRACT Traditional approaches to drug development for Alzheimer s disease are becoming increasingly expensive and in many cases disappointingly unsuccessful Based on preliminary in vitro and in vivo studies we have identified a novel small molecule methyl dimethyl oxo dihydrobenzo c naphthyridine carboxylate UK that significantly decreases A production and pro in ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health